comparemela.com

Latest Breaking News On - Athira pharma - Page 8 : comparemela.com

$1 5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying - Athira Pharma (NASDAQ:ATHA), Collective Audience (NASDAQ:CAUD)

The Dow Jones index closed lower by around 20 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Jamesf lynchAthira pharmaJoseph edelmanThomasj shawPeter bordesNadine wattGlobalstar incAthira pharma incRetractable technologies incDow jonesAudience incRetractable technologiesRetractable technologies doesAthira pharma doesHow to earnMonth from annaly capital management stock

Insider Buying: Athira Pharma, Inc (NASDAQ:ATHA) Director Acquires $73,265 52 in Stock

Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) Director Perceptive Advisors Llc purchased 32,134 shares of the stock in a transaction on Wednesday, December 27th. The shares were purchased at an average cost of $2.28 per share, with a total value of $73,265.52. Following the transaction, the director now owns 4,829,412 shares of the company’s […]

United statesAthira pharmaPerceptive advisors llcLaird norton trust companySecurities exchange commissionJacobs levy equity management incNan fung group holdings ltdAthira pharma company profileAmerican century companies incAthira pharma incGet free reportDirector perceptive advisors llcExchange commissionAdvisors llcCentury companiesLevy equity management

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the.

Athira pharmaHow is athira pharmaCash burn changing overShould we worry about athira pharmaFree cash flow

Athira Pharma (ATHA) Reports Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton

Athira Pharma (ATHA) Reports Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Mark littonHans moebiusAthira pharma incKevin churchAthira pharmaChief medical officerChief scientific officerChief executive officer

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson s Disease Dementia and Dementia with Lewy Bodies

Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative.

United statesAthira pharmaMark littonJulie rathbunHans moebiusExchange commissionAthira pharma incKevin churchSecurities exchangeChief medical officerChief scientific officerChief executive officerGlobal statistical testSecurities actSecurities exchange actPrivate securities litigation reform act

vimarsana © 2020. All Rights Reserved.